

Highlights of This Issue 871

SMALL MOLECULE THERAPEUTICS

873 Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis

Olga Karginova, Claire M. Weekley, Akila Raoul, Alhareth Alsayed, Tong Wu, Steve Seung-Young Lee, Chuan He, and Olufunmilayo I. Olopade

886 BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway

Xiaohui Chen, Xihua Cao, Xuhuang Tu, Gulimiran Alitongbieke, Zebin Xia, Xiaotong Li, Ziwen Chen, Meimei Yin, Dan Xu, Shangjie Guo, Zongxi Li, Liqun Chen, Xindao Zhang, Dingyu Xu, Meichun Gao, Jie Liu, Zhiping Zeng, Hu Zhou, Ying Su, and Xiao-kun Zhang

900 HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy

Siyu Deng, Qianwen Hu, Heng Zhang, Fang Yang, Cheng Peng, and Chuanxin Huang

909 Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Nicolas Floc'h, Susan Ashton, Douglas Ferguson, Paula Taylor, Larissa S. Carnevalli, Adina M. Hughes, Emily Harris, Maureen Hattersley, Shenghua Wen, Nicola J. Curtis, James E. Pilling, Lucy A. Young, Kim Maratea, Elizabeth J. Pease, and Simon T. Barry

920 TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X

Kimihito Ito, Makoto Nishio, Masanori Kato, Haruyasu Murakami, Yoshimi Aoyagi, Yuichiro Ohe, Takashige Okayama, Akihiro Hashimoto, Hirokazu Ohsawa, Gotaro Tanaka, Katsumasa Nonoshita, Satoru Ito, Kenichi Matsuo, and Kazutaka Miyadera

929 Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors

Sudan N. Loganathan, Nan Tang, Albert E. Holler, Nenghui Wang, and Jialiang Wang

937 Vemurafenib Inhibits Active PTK6 in *PTEN*-null Prostate Tumor Cells

Darren J. Wozniak, Ben Hitchinson, Milica B. Gilic, Wenjun Bie, Vadim Gaponenko, and Angela L. Tyrer

947 Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice

Rong Wang, Tadaaki Yamada, Sachiko Arai, Koji Fukuda, Hirokazu Taniguchi, Azusa Tanimoto, Akihiro Nishiyama, Shinji Takeuchi, Kaname Yamashita, Koshiro Ohtsubo, Junji Matsui, Naoyoshi Onoda, Eishu Hirata, Shu Taira, and Seiji Yano

957 RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer

Erik T. Goka, Pallavi Chaturvedi, Dayrelis T. Mesa Lopez, Adriana De La Garza, and Marc E. Lippman

LARGE MOLECULE THERAPEUTICS

969 GnRH-R-Targeted Lytic Peptide Sensitizes *BRCA* Wild-type Ovarian Cancer to PARP Inhibition

Shaolin Ma, Sunila Pradeep, Alejandro Villar-Prados, Yunfei Wen, Emine Bayraktar, Lingeowda S. Mangala, Mark Seungwook Kim, Sherry Y. Wu, Wei Hu, Cristian Rodriguez-Aguayo, Carola Leuschner, Xiaoyan Liang, Prahlad T. Ram, Katharina Schlacher, Robert L. Coleman, and Anil K. Sood

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

980 Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer

Koichi Kitagawa, Reina Gono, Maho Tatsumi, Masahide Kadowaki, Takane Katayama, Yoshiko Hashii, Masato Fujisawa, and Toshiro Shirakawa

991 Prospective Clinical Sequencing of Adult Glioma

Siyuan Zheng, Kristin Alfaro-Munoz, Wei Wei, Xiaojing Wang, Fang Wang, Agda Karina Eterovic, Kenna R. Mills Shaw, Funda Meric-Bernstam, Gregory N. Fuller, Ken Chen, Roel G. Verhaak, Gordon B. Mills, W.K. Alfred Yung, Shiao-Pei Weathers, and John F. de Groot

Table of Contents

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 1001** Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies



Rebecca Shatsky, Barbara A. Parker, Nam Q. Bui, Teresa Helsten, Richard B. Schwab, Sarah G. Boles, and Razelle Kurzrock



AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org


MODELS AND TECHNOLOGIES

- 1012** Preclinical Investigation of ^{212}Pb -DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model

Tania A. Rozgaja Stallons, Amal Saidi, Izabela Tworowska, Ebrahim S. Delpassand, and Julien J. Torgue

ABOUT THE COVER

Intracellular copper transport is a potential target for breast cancer therapy. Karginova and colleagues demonstrate that inhibition of intracellular copper transport with the small molecule DCAC50 triggers apoptosis in breast cancer cells and suppresses angiogenesis. To visualize the anti-angiogenic effect of DCAC50, transparent tissue tomography was applied. The cover illustrates CD31+ blood vessels in a tumor macrosection obtained from a mouse after treatment with DCAC50 and reveals significantly reduced angiogenesis compared to vehicle control. For more information, please see the full article beginning on page 873.



Molecular Cancer Therapeutics

18 (5)

Mol Cancer Ther 2019;18:871-1021.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/5>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/5>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.